Serina Therapeutics (Serina Therapeutics) FCF Margin % : 0.00% (As of Jun. 2023)

View and export this data going back to 2024. Start your Free Trial

What is Serina Therapeutics FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Serina Therapeutics's Free Cash Flow for the six months ended in Jun. 2023 was $-1.89 Mil. Serina Therapeutics's Revenue for the six months ended in Jun. 2023 was $0.00 Mil. Therefore, Serina Therapeutics's FCF Margin % for the quarter that ended in Jun. 2023 was 0.00%.

As of today, Serina Therapeutics's current FCF Yield % is -13.52%.

The historical rank and industry rank for Serina Therapeutics's FCF Margin % or its related term are showing as below:

SER' s FCF Margin % Range Over the Past 10 Years
Min: -624.6 Med: -247.41 Max: -77.62
Current: -624.6

During the past 2 years, the highest FCF Margin % of Serina Therapeutics was -77.62%. The lowest was -624.60%. And the median was -247.41%.

SER's FCF Margin % is ranked worse than
69.54% of 1044 companies
in the Biotechnology industry
Industry Median: -146.375 vs SER: -624.60

Serina Therapeutics FCF Margin % Historical Data

The historical data trend for Serina Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Serina Therapeutics FCF Margin % Chart

Serina Therapeutics Annual Data

Trend

Dec21

Dec22

FCF Margin %

-77.62

-417.20

Serina Therapeutics Semi-Annual Data
	Dec21	Jun22	Dec22	Jun23
FCF Margin %	-	-168.00	-	-

Competitive Comparison of Serina Therapeutics's FCF Margin %

For the Biotechnology subindustry, Serina Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Serina Therapeutics's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Serina Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Serina Therapeutics's FCF Margin % falls into.

Serina Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Serina Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2022 is calculated as

FCF Margin	=	Free Cash Flow (A: Dec. 2022 )	/	Revenue (A: Dec. 2022 )
	=	-2.086	/	0.5
	=	-417.20 %

Serina Therapeutics's FCF Margin for the quarter that ended in Jun. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Jun. 2023 )	/	Revenue (Q: Jun. 2023 )
	=	-1.888	/	0
	=	%

Serina Therapeutics FCF Margin % Related Terms

Thank you for viewing the detailed overview of Serina Therapeutics's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Serina Therapeutics (Serina Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Serina Therapeutics Inc (AMEX:SER) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

601 Genome Way, Suite 2001, Huntsville, AL, USA, 35806

Website

https://www.serinatherapeutics.com

Serina Therapeutics Inc is a clinical-stage biotechnology company developing a pipeline of wholly-owned drug product candidates to treat neurological diseases and pain. Serina's POZ Platform delivery technology is engineered to provide control in drug loading and more precision in the rate of release of attached drugs, enabling the potential of certain challenging small molecules, while addressing the limitations of polyethylene glycol (PEG) and other biocompatible polymers.

Serina Therapeutics (Serina Therapeutics) Headlines

From GuruFocus

Enable Injections and Serina Therapeutics Announce Agreement to Develop SER-252 in Combination with enFuse� for Advanced Parkinson's Disease

By Marketwired • 05-15-2024